Piper Sandler Downgrades Galera Therapeutics to Neutral, Lowers Price Target to $0.5
Portfolio Pulse from richadhand@benzinga.com
Piper Sandler analyst Edward Tenthoff has downgraded Galera Therapeutics (NASDAQ:GRTX) from Overweight to Neutral and lowered the price target from $6 to $0.5.
August 10, 2023 | 9:35 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Galera Therapeutics has been downgraded from Overweight to Neutral by Piper Sandler, with a significant reduction in price target from $6 to $0.5.
The downgrade from Overweight to Neutral by Piper Sandler, coupled with a significant reduction in price target, indicates a less optimistic outlook for Galera Therapeutics. This could potentially lead to a decrease in the stock's price in the short term.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100